NCT04185922 is a NA clinical trial of Hemopatch in Prostate Cancer, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT04185922?

NCT04185922 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04185922?

Interventions in NCT04185922: Hemopatch.

What condition does NCT04185922 study?

NCT04185922 studies Prostate Cancer.

Is NCT04185922 still recruiting?

NCT04185922 is currently completed. Last updated 27 June 2022.

Last reviewed 2022-06-27 · How we verify

NCT04185922

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemopatch to Prevent Lymphatic Leak After Robotic Prostatectomy and Pelvic Lymph Node Dissection

Completed NA Last updated 27 June 2022

What this trial tests

NA trial testing Hemopatch in Prostate Cancer in 32 participants. Completed in 10 June 2022.

Timeline

27 February 2020

Primary endpoint
21 July 2021

10 June 2022

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	27 February 2020
Primary completion	21 July 2021
Estimated completion	10 June 2022
Sites	1 location across Hong Kong

Drugs / interventions tested

Hemopatch

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Robotic prostatectomy (RARP) is a surgery for treatment localized prostate cancer. Bilateral pelvic lymph node dissection (BPLND) will also be performed if there is an estimated risk of occult nodal metastases exceeding 5%. BPLND in general is a well-tolerated procedure. Lymphatic leak is one of the possible complications after lymph node dissection (BPLND). Lymphocele is a collection of lymphatic fluid after operation. Hemopatch is a material used during operation that may prevent lymphorrhoea. This is a randomizedcontrolled trial that aims at investigating the application of Hemopatch to raw lymphatic tissue in preventing lymphorrhoea. Patients would be divided into 2 groups: with or without the use of Hemopatch during operation. They will be followed up on day 30 to monitor the course of recovery and any complications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial.
Teoh JY, Liu AQ, Yuen VW, Lai FP, et al · · 2022 · cited 3× · PMID 36139636 · DOI 10.3390/cancers14184476

Verify or expand the search:

Other trials of Hemopatch

Trials testing the same drug.

NCT04185480 — Evaluating Hemopatch in Reducing Seroma Related Complications Following Axillary Lymph Node Dissection: a Pilot Study · NA · completed
NCT03993067 — Hemopatch as a Tool to Prevent Biliary Fistula in Liver Surgery. · NA · completed
NCT03410914 — Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following · Phase 2 · completed
NCT03450265 — Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary Resection · NA · completed
NCT03419676 — Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy · Phase 3 · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04185922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 27 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing